Not long after the U.S. Food and Drug Administration (FDA) approved Nuplazid for use in Parkinson’s disease patients, the drug was linked to drug-related reports of deaths.
The drug was approved under the FDA’s Breakthrough Therapy process, which allows a drug to be expedited and rushed to market without a great deal of pre-market testing. The drug risks led medical professionals to question prescription error at all to Parkinson’s patients.
Nuplazid (pimavanserin) was developed by Acadia Pharmaceuticals, and was the only drug approved by the FDA to treat hallucinations, delusions, and psychosis experienced by some Parkinson’s disease patients.
Common side effects associated with Nuplazid are peripheral edema and confusional state, and the drug has a “black box warning” about the risk of death. The warning says elderly patients “treated with antipsychotic drugs” are at an increased risk of death.
Medical researchers have said that they are uncertain if Nuplazid is directly the cause of the death in Parkinson’s patients, though consumer safety advocates argue the drug is very dangerous and adverse reactions are common for those prescribed the drug.
Joe Lyon is a highly-rated Product Liability Attorney and Nuplazid Lawyer investigating cases of injury and wrongful death for plaintiffs nationwide.
Contact a Nuplazid Lawyer Following Injury
Drug manufacturers has a duty to protect consumers and warn them properly of the risks linked to their products. When pharmaceuticals are associated with injuries and deaths, it is prudent to contact a product liability attorney to review your personal case and to assess the legal options at your disposal.
